Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk. Circulation. 2015 Oct 27; 132(17):1648-66.
View in:
PubMed
subject areas
Adipocytes
Animals
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Brain
Cardiovascular Diseases
Cholesterol, LDL
Clinical Trials as Topic
Genetic Predisposition to Disease
Humans
Hyperlipoproteinemias
Incidence
Intestinal Mucosa
Liver
Mice
Molecular Targeted Therapy
Mutation
Oligonucleotides, Antisense
Peptide Fragments
Proprotein Convertase 9
Proprotein Convertases
Protein Structure, Tertiary
Receptors, LDL
RNA Interference
RNA, Small Interfering
Serine Endopeptidases
Structure-Activity Relationship
authors with profiles
Binh Phan